Related references
Note: Only part of the references are listed.Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis
Ivan Alvarez-Twose et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
The Hsp32 Inhibitors SMA-ZnPP and PEG-ZnPP Exert Major Growth-Inhibitory Effects on CD34+/CD38+ and CD34+/CD38- AML Progenitor Cells
H. Herrmann et al.
CURRENT CANCER DRUG TARGETS (2012)
Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal
Peter Valent et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2012)
Stem Cell Factor Programs the Mast Cell Activation Phenotype
Tomonobu Ito et al.
JOURNAL OF IMMUNOLOGY (2012)
Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit
Alexander Gerbaulet et al.
BLOOD (2011)
The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor
Peilin Ma et al.
BLOOD (2011)
Systemic Mastocytosis
Tracy I. George et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis
David Gonzalez-de-Olano et al.
IMMUNOTHERAPY (2011)
Mechanisms of STAT Protein Activation by Oncogenic KIT Mutants in Neoplastic Mast Cells
Amandine Chaix et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Regulation of Mast Cell Responses in Health and Disease
Alasdair M. Gilfillan et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2011)
Pediatric Mastocytosis Is a Clonal Disease Associated with D816V and Other Activating c-KIT Mutations
Christine Bodemer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Advances in mast cell biology: new understanding of heterogeneity and function
T. C. Moon et al.
MUCOSAL IMMUNOLOGY (2010)
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives
Michel Arock et al.
EXPERT REVIEW OF HEMATOLOGY (2010)
Mastocytosis An Unusual Clonal Disorder of Bone Marrow-Derived Hematopoietic Progenitor Cells
Hans-Peter Horny
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis
Christian Baumgartner et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation
Karl M. Hoffmann et al.
BLOOD (2008)
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade
Noria Harir et al.
BLOOD (2008)
Comparison of short term in vitro cultured human mast cells from different progenitors -: Peripheral blood-derived progenitors generate highly mature and functional mast cells
Hanne Busk Andersen et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2008)
Unique effects of KIT D816V in BaF3 cells: Induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens
Matthias Mayerhofer et al.
JOURNAL OF IMMUNOLOGY (2008)
The development of allergic inflammation
Stephen J. Galli et al.
NATURE (2008)
Immunomodulatory mast cells: negative, as well as positive, regulators of immunity
Stephen J. Galli et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT
Karoline Gleixner et al.
HAEMATOLOGICA (2007)
Mastocytosis and allergy
Matthew Greenhawt et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2007)
Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria
P. Valent et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis
Neil P. Shah et al.
BLOOD (2006)
Differentiation and maintenance of mast cells from CD34+ human cord blood cells
T Yoshikubo et al.
EXPERIMENTAL HEMATOLOGY (2006)
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
JP Zappulla et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Rapidly changing perspectives about mast cells at mucosal surfaces
H Vliagoftis et al.
IMMUNOLOGICAL REVIEWS (2005)
Activation mutations of human c-KIT resistant to imatinib, mesylate are sensitive to the tyrosine kinase inhibitor PKC412
JD Growney et al.
BLOOD (2005)
Mastocytosis: Pathology, genetics, and current options for therapy
P Valent et al.
LEUKEMIA & LYMPHOMA (2005)
Kit and FCεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells
TR Hundley et al.
BLOOD (2004)
Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia;: activation following aggregation of FcεRI or FcγRI
AS Kirshenbaum et al.
LEUKEMIA RESEARCH (2003)
Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
C Akin et al.
EXPERIMENTAL HEMATOLOGY (2003)
Signal transduction by several KIT juxtamembrane domain mutations
N Casteran et al.
ONCOGENE (2003)
Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene
M Sundstrom et al.
IMMUNOLOGY (2003)
Analyzing the roles of mast cells and basophils in host defense and other biological responses
SJ Galli et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2002)
The human mast cell: Functions in physiology and disease
G Krishnaswamy et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2001)
Diagnostic criteria and classification of mastocytosis:: a consensus proposal
P Valent et al.
LEUKEMIA RESEARCH (2001)
Inhibition of IgE-induced activation of human mast cells by IL-10
B Royer et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2001)